Orthosteric/allosteric bitopic ligands going hybrid with GPCRs

Molecular Interventions

Volumn 9, Issue 3, 2009, Pages 125-135

  Valant, Celine ^a   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6' GUANIDINONALTRINDOLE; [4 [(3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYL]TRIMETHYLAMMONIUM; AC 42; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIMER; DIVALENT CATION; G PROTEIN COUPLED RECEPTOR; GUANIDINE DERIVATIVE; ICI 1 18551; ISOPRENALINE; KDN 21; LY 2033298; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NORCLOZAPINE; OLIGOMER; OPIATE AGONIST; PROPRANOLOL; SEROTONIN RECEPTOR; THRX 160209; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING AFFINITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HYBRID; PHARMACOPHORE; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; DRUG DESIGN; KINETICS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED;

EID: 67650489125     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.9.3.6     Document Type: Review

References (57)

1. Lagerstrom, M.C. and Schioth, H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339-357 (2008).
2. Overington, J.P., Al-Lazikani, B., and Hopkins, A.L. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996 (2006).
3. Kenakin, T. Efficacy as a vector: The relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 65, 2-11 (2004).
4. Christopoulos, A. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198-210 (2002).
5. May, L.T., Leach, K., Sexton, P.M., and Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1-51 (2007). A comprehensive overview of GPCR allosteric modulation.
6. Milligan, G. G protein-coupled receptor dimerization: Function and ligand pharmacology. Mol. Pharmacol. 66, 1-7 (2004).
7. Urban, J.D., Clarke, W.P., von Zastrow, M. et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13 (2007). A recent overview on the concepts of stimulusbias and functional selectivity at GPCRs.
8. Schwyzer, R. ACTH: A short introductory review. Ann. N.Y. Acad. Sci. 297, 3-26 (1977). This is one of the first papers to formalize the "message-address" concept.
9. Portoghese, P.S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 10, 230-235 (1989). An early and important review on the utility of bivalent GPCR ligands.
10. Messer, W.S., Jr. Bivalent ligands for G protein-coupled receptors. Curr. Pharm. Des. 10, 2015-2020 (2004).
11. Brucke, F. Dicholinesters of alpha, omega-dicarboxylic acids and related substances. Pharmacol. Rev. 8, 265-335 (1956).
12. Erez, M., Takemori, A.E., and Portoghese, P.S. Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites. J. Med. Chem. 25, 847-849 (1982). An early example of the directed design of bivalent GPCR ligands.
13. Portoghese, P.S., Larson, D.L., Sayre, L.M., Yim, C.B., Ronsisvalle, G., Tam, S.W., and Takemori, A.E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J. Med. Chem. 29, 1855-1861 (1986).
14. Portoghese, P.S., Larson, D.L., Yim, C.B., Sayre, L.M., Ronsisvalle, G., Lipkowski, A.W., Takemori, A.E., Rice, K.C., and Tam, S.W. Stereostructure- activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. J. Med. Chem. 28, 1140-1141 (1985).
15. Christopoulos, A., Grant, M.K., Ayoubzadeh, N., Kim, O.N., Sauerberg, P., Jeppesen, L., and El-Fakahany, E.E. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J. Pharmacol. Exp. Ther. 298, 1260-1268 (2001).
16. Melchiorre, C., Minarini, A., Angeli, P., Giardina, D., Gulini, U., and Quaglia, W. Polymethylene tetraamines as muscarinic receptor probes. Trends Pharmacol. Sci. Suppl. 55-59 (1989).
17. Rajeswaran, W.G., Cao, Y., Huang, X.P. et al. Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2, 5-thiadiazole derivatives as selective muscarinic agonists. J. Med. Chem. 44, 4563-4576 (2001).
18. Halazy, S., Perez, M., Fourrier, C. et al. Serotonin dimers: Application of the bivalent ligand approach to the design of new potent and selective 5-HT1B/1D agonists. J. Med. Chem. 39, 4920-4927 (1996).
19. Soulier, J.L., Russo, O., Giner, M. et al. Design and synthesis of specific probes for human 5-HT4 receptor dimerization studies. J. Med. Chem. 48, 6220-6228 (2005).
20. Bonger, K.M., van den Berg, R.J., Heitman, L.H., IJzerman, A.P., Oosterom, J., Timmers, C.M., Overkleeft, H.S., and van der Marel, G.A. Synthesis and evaluation of homo-bivalent GnRHR ligands. Bioorg. Med. Chem. 15, 4841-4856 (2007).
21. Sharma, S.K., Jones, R.M., Metzger, T.G., Ferguson, D.M., and Portoghese, P.S. Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5′- to 6′-position of naltrindole. J. Med. Chem. 44, 2073-2079 (2001).
22. Waldhoer, M., Fong, J., Jones, R.M., Lunzer, M.M., Sharma, S.K., Kostenis, E., Portoghese, P.S., and Whistler, J.L. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U.S.A. 102, 9050-9055 (2005). This paper outlines the discovery of a heterodimer selective GPCR ligand that was originally designed based on the message-address concept.
23. 2 phenotypes. Selective targeting of δ-κ heterodimers. J. Med. Chem. 47, 2969-2972 (2004).
24. 1 receptor ligands. J. Med. Chem. 51, 6128-6137 (2008).
25. Howl, J., Langel, U., Hawtin, S.R., Valkna, A., Yarwood, N.J., Saar, K., and Wheatley, M. Chimeric strategies for the rational design of bioactive analogs of small peptide hormones. FASEB J. 11, 582-590 (1997).
26. Perez, M., Jorand-Lebrun, C., Pauwels, P.J., Pallard, I., and Halazy, S. Dimers of 5HT1 ligands preferentially bind to 5HT1B/1D receptor subtypes. Bioorg. Med. Chem. Lett. 8, 1407-1412 (1998).
27. Conn, P.J., Christopoulos, A., and Lindsley, C.W. Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41-54 (2009).
28. 1 receptor. Mol. Pharmacol. 68, 1484-1495 (2005). This paper provides a striking example of divergent effects on orthosteric ligand affinity versus efficacy by an allosteric GPCR modulator.
29. Langmead, C.J. and Christopoulos, A. Allosteric agonists of 7TM receptors: Expanding the pharmacological toolbox. Trends Pharmacol. Sci. 27, 475-481 (2006).
30. 4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 105, 10978-10983 (2008).
31. Nawaratne, V., Leach, K., Suratman, N., Loiacono, R.E., Felder, C.C., Armbruster, B.N., Roth, B.L., Sexton, P.M., and Christopoulos, A. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol. Pharmacol. 74, 1119-1131 (2008).
32. Christopoulos, A. and Kenakin, T. G Protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374 (2002).
33. Ehlert, F.J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33, 187-194 (1988).
34. Hall, D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation. Mol. Pharmacol. 58, 1412-1423 (2000).
35. Kenakin, T. New concepts in drug discovery: Collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4, 919-927 (2005).
36. Leach, K., Sexton, P.M., and Christopoulos, A. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 28, 382-389 (2007). This review provides examples of allosteric modulator-engendered functional selectivity.
37. Azzi, M., Charest, P.G., Angers, S., Rousseau, G., Kohout, T., Bouvier, M., and Piñeyro, G. β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 100, 11406-11411 (2003). This paper provides one of the earliest and most striking examples of reversals of efficacy of an orthosteric ligand depending on the signal pathway being investigated.
38. 2-adrenoceptor provide evidence for agonist-directed signaling. Mol. Pharmacol. 64, 1357-1369 (2003).
39. Galandrin, S., Oligny-Longpre, G., and Bouvier, M. The evasive nature of drug efficacy: Implications for drug discovery. Trends Pharmacol. Sci. 28, 423-430 (2007).
40. Berg, K.A., Dunlop, J., Sanchez, T., Silva, M., and Clarke, W.P. A conservative, single-amino acid substitution in the second cytoplasmic domain of the human serotonin 2C receptor alters both ligand-dependent and -independent receptor signaling. J. Pharmacol. Exp. Ther. 324, 1084-1092 (2008).
41. Antony, J., Kellershohn, K., Mohr-Andra, M. et al. Dualsteric GPCR targeting: A novel route to binding and signaling pathway selectivity. FASEB J. 23, 442-450 (2009). This is an excellent example of the design, synthesis and validation of the bitopic ligand approach, including engendering receptor selectivity in native tissues.
42. Disingrini, T., Muth, M., Dallanoce, C., Barocelli, E., Bertoni, S., Kellershohn, K., Mohr, K., De Amici, M., and Holzgrabe, U. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J. Med. Chem. 49, 366-372 (2006). This is the first publication describing the empirical design of a bitopic GPCR orthosteric/allosteric ligand.
43. Steinfeld, T., Mammen, M., Smith, J.A., Wilson, R.D., and Jasper, J.R. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol. Pharmacol. 72, 291-302 (2007).
44. Valant, C., Gregory, K.J., Hall, N.E., Scammells, P.J., Lew, M.J., Sexton, P.M., and Christopoulos, A. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 283, 29312-29321 (2008). This is the first paper identifying a bitopic mechanism as the basis of selectivity of a previously known functionally selective GPCR agonist.
45. Gregory, K.J., Sexton, P.M., and Christopoulos, A. Allosteric modulation of muscarinic acetylcholine receptors. Curr. Neuropharmacol. 5, 157-167 (2007).
46. Caulfield, M.P. and Birdsall, N.J. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50, 279-290 (1998).
47. Birdsall, N.J.M., Burgen, A.S.V., Hulme, E.C., Stockton, J.M., and Zigmond, M.J. The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart. Br. J. Pharmacol. 78, 257-259 (1983).
48. May, L.T., Avlani, V.A., Langmead, C.J., Herdon, H.J., Wood, M.D., Sexton, P.M., and Christopoulos, A. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol. Pharmacol. 72, 463-476 (2007).
49. Waelbroeck, M. Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors. Mol. Pharmacol. 46, 685-692 (1994).
50. Griffin, M.T., Figueroa, K.W., Liller, S., and Ehlert, F.J. Estimation of agonist activity at G protein-coupled receptors: Analysis of M2 muscarinic receptor signaling through Gi/o, Gs, and G15. J. Pharmacol. Exp. Ther. 321, 1193-1207 (2007).
51. Jones, C.K., Brady, A.E., Davis, A.A. et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 28, 10422-10433 (2008).
52. Langmead, C.J., Austin, N.E., Branch, C.L. et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br. J. Pharmacol. 154, 1104-1115 (2008).
53. Lebon, G., Langmead, C.J., Tehan, B.G., and Hulme, E.C. Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol. Pharmacol. 75, 331-341 (2009).
54. Spalding, T.A., Ma, J.N., Ott, T.R., Friberg, M., Bajpai, A., Bradley, S.R., Davis, R.E., Brann, M.R., and Burstein, E.S. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: Evidence for three distinct modes of receptor activation. Mol. Pharmacol. 70, 1974-1983 (2006).
55. Spalding, T.A., Trotter, C., Skjaerbaek, N., Messier, T.L., Currier, E.A., Burstein, E.S., Li, D., Hacksell, U., and Brann, M.R. Discovery of an ectopic activation site on the M1 muscarinic receptor. Mol. Pharmacol. 61, 1297-1302 (2002).
56. Sur, C., Mallorga, P.J., Wittmann, M. et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-daspartate receptor activity. Proc. Natl. Acad. Sci. U.S.A. 100, 13674-13679 (2003).
57. 2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 280, 22165-22171 (2005).